V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) antibody

Antigen: V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2)

Synonyms: Neu, HER2, HER-2, c-neu, Erbb-2, c-erbB2, mKIAA3023, NEU, NGL, TKR1, CD340, HER-2/neu

Clonality: Monoclonal (BV5)

Host: Rabbit

Reactivity: Human

Conjugate: Un-conjugated

Application: Immunohistochemistry (IHC)

Catalog no.: ABIN197686

Additional Information

Alternative name: HER-2/neu

Immunogen: A synthetic cyclic peptides from the antigen

Format: Concentrated

Isotype: IgG

Clone: BV5

Specificity: HER2/neu (also known as c-erbB-2) is a member of the epidermal growth factor receptor (EGFR) family and is notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-bound tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is a proto-oncogene located at the long arm of human chromosome 17(17q11.2-q12). Approximately 25-30 percent of breast cancers have an amplification of the HER2/neu gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. Because of its prognostic role as well as its ability to predict response to trastuzumab, breast tumors are routinely checked for overexpression of HER2/neu. Overexpression also occurs in other cancer such as osteosarcoma, ovarian cancer and stomach cancer.

Application Details

Application Notes: Titer/Working Dilution: This antibody may be diluted to a titer of 1:50 to 1:100 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30-60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Angiosarcoma. Cellular localization: Membrane

Concentration: 100ug/ml approximately

Purification: Concentrated

Buffer: This antibody is supplied as cell culture supernatant and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Storage: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Restrictions: For Research Use. CE-certified for In Vitro Diagnostics (IVD) Use in the European Union

Publications

Wright, Nicholson, Angus et al.: "Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer." in: British journal of cancer, Vol. 65, Issue 1, pp. 118-21, 1992 (PubMed).

Wright, Angus, Nicholson et al.: "Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer." in: Cancer research, Vol. 49, Issue 8, pp. 2087-90, 1989 (PubMed).

Slamon, Clark, Wong et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene." in: Science (New York, N.Y.), Vol. 235, Issue 4785, pp. 177-82, 1987 (PubMed).

Keshgegian, Cnaan: "erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody." in: American journal of clinical pathology, Vol. 108, Issue 4, pp. 456-63, 1997 (PubMed).

Gorlick, Huvos, Heller et al.: "Expression of HER2/erbB-2 correlates with survival in osteosarcoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 17, Issue 9, pp. 2781-8, 2000 (PubMed).

Jacobs, Gown, Yaziji et al.: "HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement." in: American journal of clinical pathology, Vol. 113, Issue 2, pp. 251-8, 2000 (PubMed).